English
  
Facebook  
VK  

28.09.2015 28.09.2015
GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma.

09.09.2015 09.09.2015
GlaxoSmithKline's inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug.

13.08.2015 13.08.2015
GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result.

13.07.2015 13.07.2015
The approximate 1 in 10 asthma patients who have severe disease do not respond to mainstay corticosteroid treatment, even in high doses. That could be because the immune response that occurs in the airways of severe asthma patients markedly differs from what is seen in mild-moderate disease, a team of researchers recently posited.

02.07.2015 02.07.2015
The U.S. Food and Drug Administration today approved the first drug for cystic fibrosis directed at treating the cause of the disease in people who have two copies of a specific mutation.

25.09.2014 25.09.2014
Anoro Ellipta, a novel inhaler containing a long-acting muscarinic receptor antagonist and a selective long-acting beta-2 adrenergic receptor agonist, may find a limited place in therapy for a small group of patients.

05.03.2014 05.03.2014
The strength of the inhaled corticosteroid (ICS) in the combination inhaler Relvar Ellipta has been highlighted in an evidence summary on the medicine’s use in asthma, produced by the National Institute for Health and Care Excellence. Concerns about the dosing of the product and also the colour and name, were previously raised by a group of respiratory pharmacists in a letter to The Journal.

14.02.2014 14.02.2014
Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.

22.01.2014 22.01.2014
Indian drug makers are eager to enter the generic inhaler combination business in the US after the drug regulator there eased guidelines for cheaper alternatives to GlaxoSmithKline (GSK)’s blockbuster respiratory drug, Advair.

07.01.2014 07.01.2014
A just-announced advisory committee set to meet in February 2014 may bring US regulators one step closer to alleviating a major shortage of asthma medication that resulted from the implementation of long-planned environmental regulations banning certain types of aerosol propellants.


News 1 - 10 из 48
Начало | Пред. | 1 2 3 4 5 | След. | Конец